

# Leadership Advisory Council Elections


## Tier 2



**Raghu Behara**

FESTO

Raghu Behara, Vice President of Life Sciences at Festo Corporation, is a proven transformative Global Business Leader with 20+ years of achievement combining leadership, innovation, and process excellence to create profitable, market-leading organizations within life sciences and global manufacturing companies, among others. His strategies include engaging all levels of the organization around the mission, strategy, and outcomes, building trust with internal stakeholders, customers, strategic partners, and the value chain. He is recognized as a highly principled leader, who builds world-class teams that are committed to both the customer and business. Raghu's specialties include: Business Leadership, Strategy and implementation, General Management, Product Development, People Leadership, Business Unit Leadership, Strategic Planning, Tactical Planning, Corporate Development, M&A, Organizational Development, Cross-Functional Team Leadership



# Leadership Advisory Council Elections


## Tier 2



**Sarindr "Ik"  
Bhumiratana**

EPIBONE

Sarindr "Ik" Bhumiratana is a Chief Scientific Officer and Co-Founder of EpiBoneInc, a clinical-stage tissue-engineering startup with a mission to repair skeletal reconstruction with stem cells-based approach. Ik received his PhD in Biomedical Engineering from Columbia University in 2012 and has more than 20 peer-reviewed scientific manuscripts, 8 patents family, and 5 book chapters. At EpiBoneInc, He leads R&D, manufacturing, regulatory and clinical teams and has recently led EpiBone's first product (a tissue engineered anatomical autologous bone graft) through midway of their first-in-human clinical trial. EpiBone is also aiming to bring several more products to clinical trials in the coming years.



# Leadership Advisory Council Elections


## Tier 2



**Shivaram Selvam**

GEORGIA INSTITUTE OF  
TECHNOLOGY

Shivaram Selvam, Ph.D., is the Associate Director of Research at the Marcus Center for Therapeutic Cell Characterization & Manufacturing (MC3M) at the Georgia Institute of Technology. His overall research interests and goals at MC3M are: (1) Identifying critical quality attributes (CQAs) specific to each cell therapy product via deep cell characterization methodologies to enable vast improvements in large-scale cell manufacturing processes and be predictive of their functional performance upon administration into the body. More specifically, identification of novel CQAs should potentially make cell therapy manufacturing reliable, reproducible, and amenable for broad clinical use and in addition, might even guide clinicians to achieving better patient outcomes. (2) Expanding the capabilities of sensor and automation technologies to propel the future of cell manufacturing. Prior to joining MC3M, his research work focused on developing regenerative treatments for unmet medical needs. For instance, my research group engineered injectable hydrogels as cell carriers for tissue repair and regeneration, employed nanoparticle-based techniques for controlled delivery of macromolecular proteins and small molecule drugs for therapeutic applications, and designed and developed fluorescent probes for bioimaging and biosensing of clinically relevant biomarkers for diagnostic, prognostic, and therapeutic evaluation of pathological conditions.




# Leadership Advisory Council Elections

## Tier 2



**Doris Taylor**  
ORGANAMET BIO

As a pioneer in cardiovascular regenerative medicine from bench to bedside, Dr. Taylor is credited with a number of important scientific breakthroughs related to cell and gene therapy, stem cell biology, and tissue engineering. Her work has been published in Nature Medicine, Circulation Research, The Journal of Molecular Biology, The Journal of Biochemistry, Journal of the American College of Cardiology (JACC), Journal of the American Medical Association (JAMA), and other top-tier scientific journals. She holds a number of invention disclosures, patent applications and patents and is the founder of multiple companies dedicated to cardiovascular repair technologies. She is a member of the Society for Women's Health Research (SWHR) Cardiovascular Working Group and the Organization for the Study of Sex Differences (OSSD). Other professional affiliations include the American Association for the Advancement of Science (AAAS), the American Heart Association (AHA), and the Federation of American Societies for Experimental Biology (FASEB), among others. She recently served on the Executive Committee for the Alliance for Regenerative Medicine (ARM). Dr. Taylor holds many honors including appointments as a Fellow for the American Heart Association (AHA), the American College of Cardiology and the European Society of Cardiology among other organizations. She has held faculty and or leadership appointments at Duke University Medical Center, University of Minnesota Medical School, Texas Heart Institute, Texas A&M University, and Rice University, as well as an honorary medical professorship in Krasnodar Russia. She has published extensively, authoring or co-authoring close to 200 scientific publications, and delivered hundreds of lectures - often keynote talks publicized online. Dr. Taylor is a sought-after speaker and is open to new engagements. Dr. Taylor has been recognized by the AHA for Top 10 Research Advances. Her work has been recognized and featured by 60 Minutes, NPR, CNN, The New York Times, The Wall Street Journal, BBC Horizon, BBC News Health, ABC News, NBC News, CBS News, Associated Press, National Public Radio, Good Morning America, Forbes, the Oprah Winfrey Show, NOVA Science Now, Discovery Channel's Through the Worm Hole with Morgan Freeman, Science Channel's Stem Cell Universe with Stephen Hawking, and numerous other worldwide media outlets.



# Leadership Advisory Council Elections

## Tier 2



**Katie Zander**

STANDARDS  
COORDINATING BODY

Catherine (Katie) B. Zander is currently a scientific program manager at the Standards Coordinating Body. She works to facilitate conversations and coordinate stakeholders within the regenerative medicine community and develop workforce development courses on standards implementation, to accelerate the creation of and the use of standards for cell and gene therapies and tissue engineering. Prior to her work at SCB, Katie was the American Society of Hematology's first AAAS Science & Technology Policy Fellow, where she worked for the U.S. House of Representatives, Committee on Energy and Commerce (Democrats). There she worked on a variety of issues ranging from drug shortages, the 21st Century Cures Act, and maternal mortality, to nuclear waste cleanup and storage and the regulation of toxic substances. Before that, as a postdoctoral fellow at the University of Alabama at Birmingham, Katie researched the rare blood disease, thrombotic thrombocytopenic purpura (TTP), and established a TTP patient education program.

